Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID‐19
Open Access
- 9 February 2022
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 65 (4) , 447-452
Abstract
Introduction/Aims: Coronavirus disease‐2019 (COVID‐19) may have a more severe course in patients with myasthenia gravis (MG). We aimed to assess severity of the infection and factors contributing to its severity in a group of MG patients, most of whom were not hospitalized.Methods: One hundred forty outpatients with MG followed between March 2020 and April 2021 were included in our study. Patients were asked to respond to a brief questionnaire in person, by telemedicine, or through electronic messages.Results: Nineteen patients tested positive for COVID‐19 by polymerase chain reaction. Two were asymptomatic. Of the 17 symptomatic patients, 11 had mild symptoms. They either had no treatment or received antivirals, antibiotics, and anticoagulants. Their myasthenia was well‐controlled before infection and was unaffected by COVID‐19. Three patients with moderate COVID‐19 required hospitalization, but not intensive care, and had full recovery. Three other patients, the oldest in the cohort, had severe disease: One patient with a postsurgery myasthenic exacerbation before the infection needed intensive care without intubation, but recovered completely; two morbidly obese patients with comorbidities required intubation and died. Corticosteroids were increased in four of the six moderate/severely affected patients. Immunosuppressive (IS) agents were generally continued. Hydroxychloroquine (HCQ) for COVID‐19 was used in one patient.Discussion: Most patients had mild COVID‐19 and all but two patients recovered. The design of the study made it possible to capture mild cases. Having well‐controlled MG before infection and absence of comorbidities likely affected the course of the infection favorably. IS did not influence the progression.Keywords
This publication has 27 references indexed in Scilit:
- Myasthenic crisis in COVID-19Journal of the Neurological Sciences, 2020
- COVID-19 and neuromuscular disordersNeurology, 2020
- Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases NetworkRevue Neurologique, 2020
- COVID‐19 in patients with myasthenia gravisMuscle & Nerve, 2020
- Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19Clinical Infectious Diseases, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Myasthenia gravis and infectious diseaseJournal of Neurology, 2018
- The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literatureJournal of Neurology, 2011
- Clinical findings in MuSK‐antibody positive myasthenia gravis: A U.S. experienceMuscle & Nerve, 2009
- Myasthenia gravisNeurology, 2000